Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tevogen Inc.TVGN · Entity 7276 | Chief Financial Officer | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tevogen Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 992,983 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 750,000 · Balance 992,983 F1: Represents a grant of restricted stock under the Tevogen Inc. (the "Company") 2024 Omnibus Incentive Plan, which will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031 (the "Performance Period"). The shares will automatically be forfeited in the event such revenue threshold is not met during Performance Period, upon termination of the Reporting Person's service with the Company for any reason, if it is determined that the Reporting Person has engaged in certain misconduct or competitive activities with the Company, in the event of transfer or attempted transfer prior to vesting, or if the award is not assumed in connection with a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock under the Tevogen Inc. (the "Company") 2024 Omnibus Incentive Plan, which will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031 (the "Performance Period"). The shares will automatically be forfeited in the event such revenue threshold is not met during Performance Period, upon termination of the Reporting Person's service with the Company for any reason, if it is determined that the Reporting Person has engaged in certain misconduct or competitive activities with the Company, in the event of transfer or attempted transfer prior to vesting, or if the award is not assumed in connection with a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 16, 2026 23:54 UTC | Tevogen Inc. TVGN · Entity 7276 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-26-001312 · form4.xml · nonDerivative · entry 1 Desai Kirti · CIK 0002011765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 992,983 F1 · shares: Represents a grant of restricted stock under the Tevogen Inc. (the "Company") 2024 Omnibus Incentive Plan, which will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031 (the "Performance Period"). The shares will automatically be forfeited in the event such revenue threshold is not met during Performance Period, upon termination of the Reporting Person's service with the Company for any reason, if it is determined that the Reporting Person has engaged in certain misconduct or competitive activities with the Company, in the event of transfer or attempted transfer prior to vesting, or if the award is not assumed in connection with a change in control. Read SEC document |
| July 10, 2026 Filed Jul 10, 2026 17:30 UTC | Tevogen Inc. TVGN · Entity 7276 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-26-000990 · form4.xml · nonDerivative · entry 1 Desai Kirti · CIK 0002011765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,983 F1 · shares: Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 17:31 UTC | Tevogen Inc. TVGN · Entity 7276 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-25-000757 · form4.xml · nonDerivative · entry 1 Desai Kirti · CIK 0002011765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,149,186 F1 · kind: Represents a gift of 100,000 shares of common stock to Shrimad Rajchandra Love and Care USA, Inc. and 200,000 shares of common stock to Shrimad Rajchandra Mission Dharampur (USA), Inc., which are charitable entities. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 16:48 UTC | Tevogen Inc. TVGN · Entity 7276 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-012327 · form4.xml · nonDerivative · entry 1 Desai Kirti · CIK 0002011765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,449,186 F1 · shares: Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on June 27, 2030, provided that the reporting person remains in service with the Issuer at such dates. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 16:30 UTC | Tevogen Inc. TVGN · Entity 7276 | PurchaseCommon Stock | 3,000 | $0.82 | $2,460.00 |
DisclosureSEC source: 0001062993-24-012592 · form4.xml · nonDerivative · entry 1 Desai Kirti · CIK 0002011765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,699,186 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 17:30 UTC | Tevogen Inc. TVGN · Entity 7276 | GrantCommon Stock | 9,696,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-24-003497 · form4.xml · nonDerivative · entry 1 Desai Kirti · CIK 0002011765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,696,186 F1 · price: On February 14, 2024, pursuant to that certain Agreement and Plan of Merger, dated as of June 28, 2023, by and among the Issuer, Semper Merger Sub, Inc., and Tevogen Bio Inc ("Tevogen"), each issued and outstanding share of common stock of Tevogen was automatically cancelled and converted into approximately 4.8481 shares of the common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.